Related Experiment Videos
Haemostatic effects of iloprost in patients with lower limb ischemia
A Trifiletti1, R Scamardi, M A Pizzoleo
1Chair of Angiology, University of Messina, Italy.
Insights
Iloprost treatment improved peripheral arterial disease symptoms by reducing markers of platelet activation and fibrin turnover. This study shows iloprost
Area of Science:
- Cardiovascular Medicine
- Hematology
Background:
- Peripheral arterial disease (PAD) is characterized by obliterative arteriopathies, leading to elevated markers of hemostasis.
- Patients with PAD exhibit significantly higher plasma levels of thrombomodulin (TM), betathromboglobulin (beta-TG), D-dimer (DD), and plasminogen activator-inhibitor (pAI-1) compared to healthy individuals.
Purpose of the Study:
- To investigate the hemostatic effects of iloprost, a prostacyclin analogue, in patients with peripheral arterial disease.
- To assess the impact of iloprost treatment on specific hemostatic markers and clinical outcomes in patients with lower limb arteriopathies.
Main Methods:
- A study involving 13 patients with lower limb obliterative arteriopathies and 10 healthy volunteers.
- Measurement of plasma levels of thrombomodulin (TM), betathromboglobulin (beta-TG), D-dimer (DD), and plasminogen activator-inhibitor (pAI-1) before and after 4 weeks of iloprost treatment (2 ng/kg/min, 6 hours/day infusion).
Main Results:
- Baseline hemostatic parameters (TM, beta-TG, DD, pAI-1) were significantly elevated in vasculopathic patients compared to controls.
- Iloprost treatment resulted in a significant decrease in plasma beta-TG and DD levels at the end of the 4-week period.
- Clinical improvement was observed in patients during and after iloprost treatment.
Conclusions:
- Iloprost treatment demonstrates clinical efficacy in patients with peripheral arterial disease.
- The observed clinical benefits may be attributed to the reduction in platelet activation and fibrin turnover, as indicated by decreased beta-TG and DD levels.
- Iloprost shows potential as a therapeutic agent for managing hemostatic dysregulation in peripheral arterial disease.
Abstract:
The aim of this study was to investigate the haemostatic effects of iloprost, a stable analogue of prostacyclin, in patients with peripheral arterial disease. In a group of 13 patients with obliterative arteriopathies of the lower limbs the plasma levels of thrombomodulin (TM), betathromboglobulin (beta-TG), D-dimer (DD) and plasminogen activator-inhibitor (pAI-1) were measured, and compared to the values obtained from 10 healthy volunteers. All the parameters were found to be significantly higher in vasculopathic patients. These haemostatic evaluations were carried out after 4 weeks of treatment with iloprost up to 2 ng/kg/min, 6 hours infusion per day. During and at the end of treatment a clinical improvement was recorded. The patients also showed a significant decrease in plasma beta-TG and DD at the end of treatment. These data suggest that iloprost exerts clinical improvement, in who may have a part the decrease of platelet activation and of fibrin turnover.